Clinical implications of microsomal prostaglandin E synthase-1 overexpression in human non-small-cell lung cancer

Hao Wei Wang, Chung Tsen Hsueh, Chien Fu Jeff Lin, Teh Ying Chou, Wen Hu Hsu, Liang Shun Wang, Yu Chung Wu

研究成果: 雜誌貢獻文章

13 引文 (Scopus)

摘要

Background: Microsomal prostaglandin E synthase-1 (mPGES-1) has recently been found to overexpress in human cancers, including non-small-cell lung cancer (NSCLC). However, the clinical value is largely unknown. The aim of this study was to investigate the associations between mPGES-1 expression in NSCLC and the clinical characteristics and survival outcome. Methods: Between 2001 and 2003, paired fresh tumorous and nontumorous samples were prospectively procured from patients undergoing surgery for NSCLC. The expression of mPGES-1 was assessed by using Western blot in 93 subjects and reverse transcriptase-polymerase chain reaction in 35. Overexpression of mPGES-1 was defined as a more than 2-fold expression in the tumorous sample compared with the corresponding nontumorous one. Immunohistochemistry was used to confirm its localization to the tumor cells. In a subset of 30 cases, cyclooxygenase-2 (COX-2) was also analyzed to assess its association with mPGES-1. Results: The protein and messenger RNA of mPGES-1 were both expressed at higher levels in the tumor samples (P <.001 and P = .006, respectively). The expressions of mPGES-1 and COX-2 were unrelated (P = .715). Overexpression of mPGES-1 protein was observed in 61 (65.6%) of 93 patients, but it was not significantly associated with the clinicopathologic characteristics or overall and disease-free survivals. However, mPGES-1 overexpression seemed to be associated with the likelihood of subsequent pulmonary metastases and a lower tendency for developing bony metastases (P = .001 and P = .006, respectively). Conclusions: Our results demonstrated that mPGES-1 was overexpressed in NSCLC, unassociated with COX-2. Overexpression of mPGES-1 per se was not a prognostic indicator, but it might be implicated in the organ preference of metastasis. Published by Springer Science+Business Media, Inc.

原文英語
頁(從 - 到)1224-1234
頁數11
期刊Annals of Surgical Oncology
13
發行號9
DOIs
出版狀態已發佈 - 九月 2006
對外發佈Yes

指紋

Non-Small Cell Lung Carcinoma
Cyclooxygenase 2
Neoplasm Metastasis
Prostaglandin-E Synthases
Neoplasms
Reverse Transcriptase Polymerase Chain Reaction
Disease-Free Survival
Proteins
Western Blotting
Immunohistochemistry
Lung
Messenger RNA
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

引用此文

Wang, H. W., Hsueh, C. T., Lin, C. F. J., Chou, T. Y., Hsu, W. H., Wang, L. S., & Wu, Y. C. (2006). Clinical implications of microsomal prostaglandin E synthase-1 overexpression in human non-small-cell lung cancer. Annals of Surgical Oncology, 13(9), 1224-1234. https://doi.org/10.1245/s10434-006-9001-4

Clinical implications of microsomal prostaglandin E synthase-1 overexpression in human non-small-cell lung cancer. / Wang, Hao Wei; Hsueh, Chung Tsen; Lin, Chien Fu Jeff; Chou, Teh Ying; Hsu, Wen Hu; Wang, Liang Shun; Wu, Yu Chung.

於: Annals of Surgical Oncology, 卷 13, 編號 9, 09.2006, p. 1224-1234.

研究成果: 雜誌貢獻文章

Wang, Hao Wei ; Hsueh, Chung Tsen ; Lin, Chien Fu Jeff ; Chou, Teh Ying ; Hsu, Wen Hu ; Wang, Liang Shun ; Wu, Yu Chung. / Clinical implications of microsomal prostaglandin E synthase-1 overexpression in human non-small-cell lung cancer. 於: Annals of Surgical Oncology. 2006 ; 卷 13, 編號 9. 頁 1224-1234.
@article{0c51f325bbdc4060a3d93586ac371ccb,
title = "Clinical implications of microsomal prostaglandin E synthase-1 overexpression in human non-small-cell lung cancer",
abstract = "Background: Microsomal prostaglandin E synthase-1 (mPGES-1) has recently been found to overexpress in human cancers, including non-small-cell lung cancer (NSCLC). However, the clinical value is largely unknown. The aim of this study was to investigate the associations between mPGES-1 expression in NSCLC and the clinical characteristics and survival outcome. Methods: Between 2001 and 2003, paired fresh tumorous and nontumorous samples were prospectively procured from patients undergoing surgery for NSCLC. The expression of mPGES-1 was assessed by using Western blot in 93 subjects and reverse transcriptase-polymerase chain reaction in 35. Overexpression of mPGES-1 was defined as a more than 2-fold expression in the tumorous sample compared with the corresponding nontumorous one. Immunohistochemistry was used to confirm its localization to the tumor cells. In a subset of 30 cases, cyclooxygenase-2 (COX-2) was also analyzed to assess its association with mPGES-1. Results: The protein and messenger RNA of mPGES-1 were both expressed at higher levels in the tumor samples (P <.001 and P = .006, respectively). The expressions of mPGES-1 and COX-2 were unrelated (P = .715). Overexpression of mPGES-1 protein was observed in 61 (65.6{\%}) of 93 patients, but it was not significantly associated with the clinicopathologic characteristics or overall and disease-free survivals. However, mPGES-1 overexpression seemed to be associated with the likelihood of subsequent pulmonary metastases and a lower tendency for developing bony metastases (P = .001 and P = .006, respectively). Conclusions: Our results demonstrated that mPGES-1 was overexpressed in NSCLC, unassociated with COX-2. Overexpression of mPGES-1 per se was not a prognostic indicator, but it might be implicated in the organ preference of metastasis. Published by Springer Science+Business Media, Inc.",
keywords = "Cyclooxygenase inhibitors, Non-small-cell lung cancer, Prostaglandin-endoperoxide synthase, Prostaglandins",
author = "Wang, {Hao Wei} and Hsueh, {Chung Tsen} and Lin, {Chien Fu Jeff} and Chou, {Teh Ying} and Hsu, {Wen Hu} and Wang, {Liang Shun} and Wu, {Yu Chung}",
year = "2006",
month = "9",
doi = "10.1245/s10434-006-9001-4",
language = "English",
volume = "13",
pages = "1224--1234",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Clinical implications of microsomal prostaglandin E synthase-1 overexpression in human non-small-cell lung cancer

AU - Wang, Hao Wei

AU - Hsueh, Chung Tsen

AU - Lin, Chien Fu Jeff

AU - Chou, Teh Ying

AU - Hsu, Wen Hu

AU - Wang, Liang Shun

AU - Wu, Yu Chung

PY - 2006/9

Y1 - 2006/9

N2 - Background: Microsomal prostaglandin E synthase-1 (mPGES-1) has recently been found to overexpress in human cancers, including non-small-cell lung cancer (NSCLC). However, the clinical value is largely unknown. The aim of this study was to investigate the associations between mPGES-1 expression in NSCLC and the clinical characteristics and survival outcome. Methods: Between 2001 and 2003, paired fresh tumorous and nontumorous samples were prospectively procured from patients undergoing surgery for NSCLC. The expression of mPGES-1 was assessed by using Western blot in 93 subjects and reverse transcriptase-polymerase chain reaction in 35. Overexpression of mPGES-1 was defined as a more than 2-fold expression in the tumorous sample compared with the corresponding nontumorous one. Immunohistochemistry was used to confirm its localization to the tumor cells. In a subset of 30 cases, cyclooxygenase-2 (COX-2) was also analyzed to assess its association with mPGES-1. Results: The protein and messenger RNA of mPGES-1 were both expressed at higher levels in the tumor samples (P <.001 and P = .006, respectively). The expressions of mPGES-1 and COX-2 were unrelated (P = .715). Overexpression of mPGES-1 protein was observed in 61 (65.6%) of 93 patients, but it was not significantly associated with the clinicopathologic characteristics or overall and disease-free survivals. However, mPGES-1 overexpression seemed to be associated with the likelihood of subsequent pulmonary metastases and a lower tendency for developing bony metastases (P = .001 and P = .006, respectively). Conclusions: Our results demonstrated that mPGES-1 was overexpressed in NSCLC, unassociated with COX-2. Overexpression of mPGES-1 per se was not a prognostic indicator, but it might be implicated in the organ preference of metastasis. Published by Springer Science+Business Media, Inc.

AB - Background: Microsomal prostaglandin E synthase-1 (mPGES-1) has recently been found to overexpress in human cancers, including non-small-cell lung cancer (NSCLC). However, the clinical value is largely unknown. The aim of this study was to investigate the associations between mPGES-1 expression in NSCLC and the clinical characteristics and survival outcome. Methods: Between 2001 and 2003, paired fresh tumorous and nontumorous samples were prospectively procured from patients undergoing surgery for NSCLC. The expression of mPGES-1 was assessed by using Western blot in 93 subjects and reverse transcriptase-polymerase chain reaction in 35. Overexpression of mPGES-1 was defined as a more than 2-fold expression in the tumorous sample compared with the corresponding nontumorous one. Immunohistochemistry was used to confirm its localization to the tumor cells. In a subset of 30 cases, cyclooxygenase-2 (COX-2) was also analyzed to assess its association with mPGES-1. Results: The protein and messenger RNA of mPGES-1 were both expressed at higher levels in the tumor samples (P <.001 and P = .006, respectively). The expressions of mPGES-1 and COX-2 were unrelated (P = .715). Overexpression of mPGES-1 protein was observed in 61 (65.6%) of 93 patients, but it was not significantly associated with the clinicopathologic characteristics or overall and disease-free survivals. However, mPGES-1 overexpression seemed to be associated with the likelihood of subsequent pulmonary metastases and a lower tendency for developing bony metastases (P = .001 and P = .006, respectively). Conclusions: Our results demonstrated that mPGES-1 was overexpressed in NSCLC, unassociated with COX-2. Overexpression of mPGES-1 per se was not a prognostic indicator, but it might be implicated in the organ preference of metastasis. Published by Springer Science+Business Media, Inc.

KW - Cyclooxygenase inhibitors

KW - Non-small-cell lung cancer

KW - Prostaglandin-endoperoxide synthase

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=33748978607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748978607&partnerID=8YFLogxK

U2 - 10.1245/s10434-006-9001-4

DO - 10.1245/s10434-006-9001-4

M3 - Article

C2 - 16952028

AN - SCOPUS:33748978607

VL - 13

SP - 1224

EP - 1234

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 9

ER -